NCT04467671View on ClinicalTrials.gov

Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
HLH - Hypoplastic Left Heart SyndromeDORVDILV - Double Inlet Left VentricleMitral AtresiaTricuspid AtresiaUnbalanced AV CanalSingle-ventricleHeart Defects, CongenitalCardiovascular AbnormalitiesCardiovascular DiseasesHeart Diseases
Interventions
COMBINATION_PRODUCT

Tissue Engineered Vascular Grafts

Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)

Trial Locations (1)

43205

RECRUITING

Nationwide Children's Hospital, Columbus

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Gunze Limited

OTHER

collaborator

National Institutes of Health (NIH)

NIH

lead

Nationwide Children's Hospital

OTHER